Forge secures $120M to increase AAV manufacturing capacity

By The Science Advisory Board staff writers

April 29, 2021 -- Contract development and manufacturing organization (CDMO) Forge Biologics has closed $120 million in financing to accelerate the expansion of its adeno-associated virus (AAV) manufacturing capabilities

In addition to increasing its current good manufacturing practice (cGMP) production capacity, the company will also use the funds to operate its subsidiaries that are advanced novel AAV gene therapy programs, including its lead program, FBX-101, a gene therapy which uses AAV to deliver a functioning copy of the galactosylceramidase (GALC) gene, for the treatment of patients with Krabbe disease.

Forge currently operates a 175,000-sq-ft, cGMP facility in Columbus, OH, that is dedicated to AAV viral vector manufacturing. The company offers end-to-end manufacturing services, including research and toxicology-grade AAV production to support gene therapy programs from preclinical through clinical and commercial stage manufacturing.

The series B financing was led by RA Capital Management.

Copyright © 2021

BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter